The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
92995245 9299524 5 F 20120924 20160822 20130521 20160902 EXP CA-ROCHE-1225823 ROCHE 45.58 YR F Y 120.00000 KG 20160902 MD CA CA

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
92995245 9299524 1 PS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 300 MG SOLUTION FOR INJECTION
92995245 9299524 2 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 300 MG SOLUTION FOR INJECTION
92995245 9299524 3 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 SOLUTION FOR INJECTION
92995245 9299524 4 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 SOLUTION FOR INJECTION
92995245 9299524 5 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 300 MG SOLUTION FOR INJECTION
92995245 9299524 6 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 SOLUTION FOR INJECTION
92995245 9299524 7 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 SOLUTION FOR INJECTION
92995245 9299524 8 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 SOLUTION FOR INJECTION
92995245 9299524 9 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 SOLUTION FOR INJECTION
92995245 9299524 10 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 SOLUTION FOR INJECTION
92995245 9299524 11 SS XOLAIR OMALIZUMAB 1 Subcutaneous U S0060A,S0062,S0065E,S0002F 103976 SOLUTION FOR INJECTION

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
92995245 9299524 1 Asthma

Outcome of event

Event ID CASEID OUTC COD
92995245 9299524 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
92995245 9299524 Blood pressure increased
92995245 9299524 Cholelithiasis
92995245 9299524 Chronic obstructive pulmonary disease
92995245 9299524 Forced expiratory volume decreased
92995245 9299524 Forced vital capacity decreased
92995245 9299524 Gastroenteritis viral
92995245 9299524 Influenza
92995245 9299524 Migraine
92995245 9299524 Muscle spasms
92995245 9299524 Respiratory disorder
92995245 9299524 Scleral discolouration
92995245 9299524 Urinary tract infection
92995245 9299524 Weight decreased
92995245 9299524 Weight increased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
92995245 9299524 1 20060109 0
92995245 9299524 2 20070108 0
92995245 9299524 3 20120924 0
92995245 9299524 4 20130128 0
92995245 9299524 5 20150420 0
92995245 9299524 6 20160215 0
92995245 9299524 7 20160314 0
92995245 9299524 8 20160404 0
92995245 9299524 9 20160509 0
92995245 9299524 10 20160725 0
92995245 9299524 11 20160822 0